U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer